BIOTRICITY INC.
For the period ended Mar 31, 2026. Filed Jul 14, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Jul 14, 2026
BTCY$0.06+7.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(Expressed in US dollars)
| Year ended March 31, 2026 | Year ended March 31, 2025 | |
|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||
| Net loss before dividends | (2,404,139) | (8,421,179) |
| Adjustments to reconcile net loss to net cash used in operations | ||
| Stock based compensation | 25,632 | 1,461,698 |
| Issuance of shares for services | 3,770 | 320,883 |
| Issuance of warrants for brokers, at fair value | 38,078 | - |
| Accretion and amortization expenses | 745,896 | 1,939,816 |
| Change in fair value of derivative liabilities | 167,349 | 553,856 |
| (Gain) Loss on debt conversion and redemption | (1,252) | 137,934 |
| Loss upon settlement of accounts payable | — | 249,093 |
| Loss on debt and warrant modification | — | — |
| Property and equipment depreciation | 5,953 | 5,953 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (1,334,260) | (110,923) |
| Operating right of use assets amortization | 465,839 | 409,540 |
| Inventory | 214,090 | 324,017 |
| Deposits and other receivables | (372,511) | (747,831) |
| Advance from Customers | 1,531,530 | - |
| Accounts payable and accrued liabilities and lease obligations | 195,070 | 1,496,966 |
| Net cash used in operating activities | (718,955) | (2,380,177) |
| CASH FLOWS FROM FINANCING ACTIVITIES | ||
| Issuance of common shares, net | — | 125,227 |
| Issuance of preferred shares, net | — | 1,732,532 |
| Redemption of preferred shares | (200,000) | - |
| Proceeds from convertible debentures, net | — | 1,835,000 |
| Proceeds from (repayment of) short term loan and promissory notes, net | 1,381,769 | (1,733,516) |
| Term Loan, net | (600,000) | - |
| Preferred Stock Dividend | (24,033) | (29,984) |
| Net cash provided by financing activities | 557,736 | 1,929,259 |
| Effect of foreign currency translation | (54,137) | 30,003 |
| Net increase (decrease) in cash during the year | (161,219) | (450,918) |
| Cash, beginning of year | 365,145 | 786,060 |
| Cash, end of year | 149,789 | 365,145 |
| Supplemental disclosure of cash flow information: | ||
| Interest paid | 2,878,857 | 3,611,939 |
| Taxes | — | — |
| Supplemental disclosure of non-cash financing activities: | ||
| Conversion of Series B notes into common stock | 433,973 | 5,950,545 |
| Conversion of convertible notes into common stock | — | 2,401,735 |
| Warrants issued and recorded as debt discount | 38,078 | — |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.